Journal
JOURNAL OF DRUG TARGETING
Volume 30, Issue 4, Pages 413-429Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2021.2013852
Keywords
SARS-CoV2; drug repurposing; pathophysiology; drug targets; clinical trials
Categories
Funding
- Department of Pharmaceuticals (DOP)
- Ministry of Chemical and Fertilizers, Govt of India
Ask authors/readers for more resources
COVID-19 is a clinical outcome of viral infection caused by beta coronavirus strain, with no satisfactory drug developed and an immediate necessity for chemotherapeutic repurposing plan. Drug repurposing is an effective strategy that saves time and costs compared to de novo drug acquisition process.
COVID-19 is a clinical outcome of viral infection emerged due to strain of beta coronavirus which attacks the type-2 pneumocytes in alveoli via angiotensin-converting enzyme 2 (ACE2) receptors. There is no satisfactory drug developed against 'SARS-CoV2', highlighting an immediate necessity chemotherapeutic repurposing plan COVID-19. Drug repurposing is a method of selection of approved therapeutics for new use and is considered to be the most effective drug finding strategy since it includes less time and cost to obtain treatment compared to the de novo drug acquisition process. Several drugs such as hydroxychloroquine, remdesivir, teicoplanin, darunavir, ritonavir, nitazoxanide, chloroquine, tocilizumab and favipiravir (FPV) showed their activity against 'SARS-CoV2' in vitro. This review has emphasized on repurposing of drugs, and biologics used in clinical set up for targeting COVID-19 and to evaluate their pharmacokinetics, pharmacodynamics and safety with their future aspect. The key benefit of drug repurposing is the wealth of information related to its safety, and easy accessibility. Altogether repurposing approach allows access to regulatory approval as well as reducing sophisticated safety studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available